Clinical trial · Observational
RESECT: Improving Quality in TURBT Surgery.
Transurethral REsection and Single Instillation Intra-vesical Chemotherapy Evaluation in Bladder Cancer Treatment (RESECT) Improving Quality in TURBT Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Superficial bladder cancer, known as non-muscle-invasive bladder cancer (NMIBC), is the most common type of bladder cancer. It is expensive to manage and significantly impacts on patients' quality of life. This is because there is a high burden of recurrent disease after initial treatment, and need for long term surveillance for recurrence. The most important step in the diagnosis and treatment of NMIBC is the first surgical procedure called the transurethral resection of bladder tumour (TURBT). There is evidence that the quality of the TURBT operation, and the use of a single administration of bladder chemotherapy following the operation, can reduce cancer recurrence rates and progression to more invasive cancer. There is anecdotal evidence that the quality of TURBT surgery and the usage of intravesical chemotherapy varies widely between hospitals and thus may result in worse outcomes for some patients. The primary objective of the study is to determine if audit and feedback can improve the quality of TURBT surgery and if this reduces recurrence of NMIBC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Performance feedback and education | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Audit only
- description
- This group of sites will participate in the audit. No performance feedback will be provided during the period under study. Feedback will be provided at the end of the study period.
- label
- Audit with feedback
- description
- This group of sites will participate in the audit, and receive a feedback intervention about their practice based on retrospective data about surgery performed before the start of the study period.
- interventionNames
- Behavioral: Performance feedback and education
Primary outcomes (4)
- measure
- The rate of detrusor muscle sampling at TURBT
- timeFrame
- At point of surgery, assessed from specimen pathology report.
- description
- The proportion of first tumour cases with tumours \>5mm in diameter where detrusor muscle is present in the specimen on histological assessment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Site inclusion criteria: Perform TURBT surgery for non-muscle invasive bladder cancer and perform at least 20 first tumour TURBT surgeries per year. Case Inclusion criteria: ● Patients undergoing transurethral surgical treatment of confirmed transitional cell carcinoma of the bladder Case Exclusion criteria * Radiologically suspected muscle invasive bladder cancer pre-operatively * Surgery not performed with curative intent: a. Diagnostic purposes only b. Symptomatic or palliative purposes only c. diffuse lesions that cannot cured by TURBT surgery * Emergency TURBT * Records lacking pre-defined minimum data set * All records from sites where the study minimum requirements are not met
References
Publications (2)
- DERIVEDOrecchia L, Gerardi M, Colalillo G, Leonardis F, Rosato E, Asimakopoulos AD, Gallagher KM, Bhatt N, Khadhouri S, Kasivisvanathan V, Finazzi Agro E, Miano R, Albisinni S. Impact of audit and feedback on transurethral resection of bladder tumour quality: a monocentric post-completion evaluation of the RESECT trial. BJU Int. 2026 Jul;138(1):92-99. doi: 10.1111/bju.70266. Epub 2026 Apr 1. PMID 41919786
- DERIVEDGallagher K, Bhatt N, Clement K, Zimmermann E, Khadhouri S, MacLennan S, Kulkarni M, Gaba F, Anbarasan T, Asif A, Light A, Ng A, Chan V, Nathan A, Cooper D, Aucott L, Marcq G, Teoh JY, Hensley P, Duncan E, Goulao B, O'Brien T, Nielsen M, Mariappan P, Kasivisvanathan V. Audit, Feedback, and Education to Improve Quality and Outcomes in Transurethral Resection and Single-Instillation Intravesical Chemotherapy for Nonmuscle Invasive Bladder Cancer Treatment: Protocol for a Multicenter International Observational Study With an Embedded Cluster Randomized Trial. JMIR Res Protoc. 2023 Jun 15;12:e42254. doi: 10.2196/42254. PMID 37318875